We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Manhattan Pharmaceuticals announced it has expanded the clinical trial sites for its ongoing Phase IIa study of oral Oleoyl-estrone (OE) in obese adult subjects to the United States.
Targacept has reported positive results from a double-blind, placebo-controlled, Phase II clinical trial of mecamylamine hydrochloride as an augmentation treatment for major depression.
Oxford BioMedica has announced the start of TRIST, a pivotal, multicenter Phase III trial of TroVax, the company's cancer immunotherapy, in patients with advanced or metastatic renal cell carcinoma (RCC).
Genta has presented new analyses from the company's randomized Phase III trial of Genasense (oblimersen sodium) injection in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
IDM Pharma has submitted a marketing authorization application in electronic format to the European Medicines Agency (EMEA) for Mepact (mifamurtide for injection), requesting approval for its use in the treatment of patients with newly diagnosed, respectable, high-grade osteosarcoma following surgical resection in combination with postoperative, multi-agent chemotherapy.
DOR BioPharma announced that it has submitted a marketing authorization application to the European Medicines Evaluation Agency for orBec (oral beclomethasone dipropionate) for the treatment of gastrointestinal graft-versus-host disease (GI GVHD), the most common life-threatening complication of allogeneic hematopoietic stem cell transplantation in cancer patients.